CWM
INO icon

Compass Wealth Management’s Inovio Pharmaceuticals INO Stock Holding History

Compass Wealth Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14
Closed -$76 – 402
2023
Q2 		$76 Hold
14
– – ﹤0.01% 405
2023
Q1 		$140 Hold
14
– – ﹤0.01% 413
2022
Q4 		$265 Buy
+14
New +$317 ﹤0.01% 407

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Compass Wealth Management's INO Position: Q3 2023 in Review

Compass Wealth Management sold out of Inovio Pharmaceuticals (INO) in Q3 2023, closing a stake of 14 shares — an estimated $76 sold.

Compass Wealth Management first reported a position in INO in Q4 2022 and held it in 3 quarters. The position peaked at $265 in Q4 2022. 124 funds tracked by Wall St. Rank hold INO as of Q3 2023.

  • Compass Wealth Management reported no remaining Inovio Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Compass Wealth Management sold 14 Inovio Pharmaceuticals shares in Q3 2023, an estimated $76.
  • Compass Wealth Management first reported a position in Inovio Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Compass Wealth Management's Inovio Pharmaceuticals position peaked at $265 in Q4 2022.
  • 124 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2023.

Based on Compass Wealth Management's 13F filing for Q3 2023, filed 25 Oct 2023.